Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects*
暂无分享,去创建一个
Natalie L. Cápiro | Y. Pang | Wenming Li | Yifan Han | Z. Mao | Jinqiu Zhu | Qian Yang | K. Pennell | D. Walker | H. She | Yingli He | L. Yao | J. Dou | Yong Liu | Leili Jia | Zixu Mao
[1] W. Severt,et al. Disease Modification in Parkinson’s Disease , 2011, Drugs & aging.
[2] W. Poewe,et al. Milestones in Parkinson's disease therapeutics , 2011, Movement disorders : official journal of the Movement Disorder Society.
[3] G. Scapagnini,et al. Modulation of Nrf2/ARE Pathway by Food Polyphenols: A Nutritional Neuroprotective Strategy for Cognitive and Neurodegenerative Disorders , 2011, Molecular Neurobiology.
[4] Y. Smith,et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. , 2011, The Journal of clinical investigation.
[5] J. Kordower,et al. α-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease , 2011, Neurobiology of Disease.
[6] Hai-Jie Yang,et al. Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3β/JNK signaling , 2010, Apoptosis.
[7] G. Miller,et al. Behavioral phenotyping of mouse models of Parkinson's disease , 2010, Behavioural Brain Research.
[8] Min Zhang,et al. Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. , 2010, Toxicology.
[9] Dik‐Lung Ma,et al. Pathologically Activated Neuroprotection via Uncompetitive Blockade of N-Methyl-d-aspartate Receptors with Fast Off-rate by Novel Multifunctional Dimer Bis(propyl)-cognitin* , 2010, The Journal of Biological Chemistry.
[10] David S. Park,et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway , 2010, Proceedings of the National Academy of Sciences.
[11] Z. Mao,et al. Phosphorylation of Neuronal Survival Factor MEF2D by Glycogen Synthase Kinase 3β in Neuronal Apoptosis* , 2009, The Journal of Biological Chemistry.
[12] C. Warren Olanow,et al. Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.
[13] M. Gearing,et al. Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy , 2009, Science.
[14] S. Mandel,et al. Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases , 2008, CNS neuroscience & therapeutics.
[15] M. Beal,et al. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.
[16] M. Beal,et al. PPAR: a therapeutic target in Parkinson’s disease , 2008, Journal of neurochemistry.
[17] Yizheng Wang,et al. Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity , 2007, Neuropharmacology.
[18] Angelika Richter,et al. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice , 2007, Journal of neuroscience research.
[19] S. Przedborski,et al. Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.
[20] M. Beal,et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.
[21] Erwan Bezard,et al. Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.
[22] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[23] David S. Park,et al. Calpain-Regulated p35/cdk5 Plays a Central Role in Dopaminergic Neuron Death through Modulation of the Transcription Factor Myocyte Enhancer Factor 2 , 2006, The Journal of Neuroscience.
[24] M. Beal,et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Li,et al. PI3K/Akt‐dependent regulation of the transcription factor myocyte enhancer factor‐2 in insulin‐like growth factor‐1‐ and membrane depolarization‐mediated survival of cerebellar granule neurons , 2005, Journal of neuroscience research.
[26] David S. Park,et al. Cyclin-Dependent Kinase 5 Mediates Neurotoxin-Induced Degradation of the Transcription Factor Myocyte Enhancer Factor 2 , 2005, The Journal of Neuroscience.
[27] Ming-tao Li,et al. Novel Dimeric Acetylcholinesterase Inhibitor Bis(7)-tacrine, but Not Donepezil, Prevents Glutamate-induced Neuronal Apoptosis by Blocking N-Methyl-d-aspartate Receptors* , 2005, Journal of Biological Chemistry.
[28] Z. Mao,et al. Regulation of Neuroprotective Activity of Myocyte-enhancer Factor 2 by cAMP-Protein Kinase A Signaling Pathway in Neuronal Survival* , 2005, Journal of Biological Chemistry.
[29] S. Friedman,et al. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. , 2004, Gastroenterology.
[30] T. Dawson,et al. Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.
[31] Z. Xia,et al. ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Cuadrado,et al. Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner* , 2003, The Journal of Biological Chemistry.
[33] Junmin Peng,et al. Cdk5-Mediated Inhibition of the Protective Effects of Transcription Factor MEF2 in Neurotoxicity-Induced Apoptosis , 2003, Neuron.
[34] Todd B. Sherer,et al. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.
[35] Jiankun Cui,et al. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. K. Meintzer,et al. Myocyte Enhancer Factor 2A and 2D Undergo Phosphorylation and Caspase-Mediated Degradation during Apoptosis of Rat Cerebellar Granule Neurons , 2001, The Journal of Neuroscience.
[37] Hui Zhang,et al. Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism , 2001, Journal of neurochemistry.
[38] M E Greenberg,et al. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.
[39] Z. Mao,et al. Calcineurin Enhances MEF2 DNA Binding Activity in Calcium-dependent Survival of Cerebellar Granule Neurons* , 1999, The Journal of Biological Chemistry.
[40] K. Prasad,et al. Multiple antioxidants in the prevention and treatment of Parkinson's disease. , 1999, Journal of the American College of Nutrition.
[41] T. Joh,et al. Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos , 1999, The Journal of Neuroscience.
[42] E. López-Martín,et al. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.
[43] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[44] S. Brimijoin,et al. Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase , 1996, The Journal of Biological Chemistry.
[45] Samuel M. Goldman,et al. EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.
[46] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[47] P. Jenner,et al. Oxidative stress in Parkinson's disease , 2003, Annals of neurology.
[48] J. Benito-León,et al. [Epidemiology of Parkinson disease]. , 1998, Neurologia.
[49] C. Olanow. Oxidative Stress in Parkinson's Disease , 1997 .